Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Analysis of an Integrated Human Multiorgan Microphysiological System for Combined Tolcapone Metabolism and Brain Metabolomics.

Wang X, Cirit M, Wishnok JS, Griffith LG, Tannenbaum SR.

Anal Chem. 2019 Jul 2;91(13):8667-8675. doi: 10.1021/acs.analchem.9b02224. Epub 2019 Jun 21.

PMID:
31181164
2.

Translational Assessment of Drug-Induced Proximal Tubule Injury Using a Kidney Microphysiological System.

Maass C, Sorensen NB, Himmelfarb J, Kelly EJ, Stokes CL, Cirit M.

CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):316-325. doi: 10.1002/psp4.12400. Epub 2019 Apr 9.

3.

Maximizing the impact of microphysiological systems with in vitro-in vivo translation.

Cirit M, Stokes CL.

Lab Chip. 2018 Jun 26;18(13):1831-1837. doi: 10.1039/c8lc00039e.

4.

Establishing quasi-steady state operations of microphysiological systems (MPS) using tissue-specific metabolic dependencies.

Maass C, Dallas M, LaBarge ME, Shockley M, Valdez J, Geishecker E, Stokes CL, Griffith LG, Cirit M.

Sci Rep. 2018 May 22;8(1):8015. doi: 10.1038/s41598-018-25971-y.

5.

Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies.

Edington CD, Chen WLK, Geishecker E, Kassis T, Soenksen LR, Bhushan BM, Freake D, Kirschner J, Maass C, Tsamandouras N, Valdez J, Cook CD, Parent T, Snyder S, Yu J, Suter E, Shockley M, Velazquez J, Velazquez JJ, Stockdale L, Papps JP, Lee I, Vann N, Gamboa M, LaBarge ME, Zhong Z, Wang X, Boyer LA, Lauffenburger DA, Carrier RL, Communal C, Tannenbaum SR, Stokes CL, Hughes DJ, Rohatgi G, Trumper DL, Cirit M, Griffith LG.

Sci Rep. 2018 Mar 14;8(1):4530. doi: 10.1038/s41598-018-22749-0.

6.

Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies.

Tsamandouras N, Chen WLK, Edington CD, Stokes CL, Griffith LG, Cirit M.

AAPS J. 2017 Sep;19(5):1499-1512. doi: 10.1208/s12248-017-0122-4. Epub 2017 Jul 27.

7.

Integrated gut/liver microphysiological systems elucidates inflammatory inter-tissue crosstalk.

Chen WLK, Edington C, Suter E, Yu J, Velazquez JJ, Velazquez JG, Shockley M, Large EM, Venkataramanan R, Hughes DJ, Stokes CL, Trumper DL, Carrier RL, Cirit M, Griffith LG, Lauffenburger DA.

Biotechnol Bioeng. 2017 Nov;114(11):2648-2659. doi: 10.1002/bit.26370. Epub 2017 Jul 27.

8.

Integrated Assessment of Diclofenac Biotransformation, Pharmacokinetics, and Omics-Based Toxicity in a Three-Dimensional Human Liver-Immunocompetent Coculture System.

Sarkar U, Ravindra KC, Large E, Young CL, Rivera-Burgos D, Yu J, Cirit M, Hughes DJ, Wishnok JS, Lauffenburger DA, Griffith LG, Tannenbaum SR.

Drug Metab Dispos. 2017 Jul;45(7):855-866. doi: 10.1124/dmd.116.074005. Epub 2017 Apr 27.

9.

Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Maass C, Stokes CL, Griffith LG, Cirit M.

Integr Biol (Camb). 2017 Apr 18;9(4):290-302. doi: 10.1039/c6ib00243a.

10.

Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System.

Tsamandouras N, Kostrzewski T, Stokes CL, Griffith LG, Hughes DJ, Cirit M.

J Pharmacol Exp Ther. 2017 Jan;360(1):95-105. Epub 2016 Oct 19.

11.

Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Marx U, Andersson TB, Bahinski A, Beilmann M, Beken S, Cassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, Gaertner C, Giese C, Griffith L, Hartung T, Heringa MB, Hoeng J, de Jong WH, Kojima H, Kuehnl J, Leist M, Luch A, Maschmeyer I, Sakharov D, Sips AJ, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tralau T, Tsyb S, van de Stolpe A, Vandebriel R, Vulto P, Wang J, Wiest J, Rodenburg M, Roth A.

ALTEX. 2016;33(3):272-321. doi: 10.14573/altex.1603161. Epub 2016 May 15. Review.

12.

Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis.

Ok E, Asci G, Bayraktaroglu S, Toz H, Ozkahya M, Yilmaz M, Kircelli F, Sevinc Ok E, Ceylan N, Duman S, Cirit M, Monier-Faugere MC, Malluche HH.

J Am Soc Nephrol. 2016 Aug;27(8):2475-86. doi: 10.1681/ASN.2015030268. Epub 2015 Dec 23.

13.

Quantitative Systems Pharmacology Approaches Applied to Microphysiological Systems (MPS): Data Interpretation and Multi-MPS Integration.

Yu J, Cilfone NA, Large EM, Sarkar U, Wishnok JS, Tannenbaum SR, Hughes DJ, Lauffenburger DA, Griffith LG, Stokes CL, Cirit M.

CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):585-94. doi: 10.1002/psp4.12010. Epub 2015 Oct 5.

14.

Physiome-on-a-Chip: The Challenge of "Scaling" in Design, Operation, and Translation of Microphysiological Systems.

Stokes CL, Cirit M, Lauffenburger DA.

CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):559-62. doi: 10.1002/psp4.12042. Epub 2015 Oct 10.

15.

Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia.

Duman N, Uyanik A, Unsal A, Sezer S, Camsari T, Cirit M, Yilmaz ME, Altun B, Duranay M, Yildiz A, Sahin I, Dogukan A, Ustundag S, Karayaylali I, Kahveci A, Sindel S, Kiykim AA, Yenicerioglu Y, Akbas E, Ozdener F.

Clin Kidney J. 2014 Oct;7(5):464-9. doi: 10.1093/ckj/sfu079. Epub 2014 Jul 29.

16.

Prognostic value of glomerular C4d staining in patients with IgA nephritis.

Sahin OZ, Yavas H, Taslı F, Gibyeli DG, Ersoy R, Uzum A, Cirit M.

Int J Clin Exp Pathol. 2014 May 15;7(6):3299-304. eCollection 2014.

17.

Data-driven modeling reconciles kinetics of ERK phosphorylation, localization, and activity states.

Ahmed S, Grant KG, Edwards LE, Rahman A, Cirit M, Goshe MB, Haugh JM.

Mol Syst Biol. 2014 Jan 30;10:718. doi: 10.1002/msb.134708. Print 2014.

18.

The value of serum immunoglobulin free light chain assessment in patients with monoclonal gammopathies and acute renal failure.

Cirit M, Uzüm A, Ozen P, Sentürk BA, Bozkaya G, Payzin B, Ural O.

Turk J Haematol. 2012 Dec;29(4):385-91. doi: 10.5505/tjh.2012.48640. Epub 2012 Dec 5.

19.

Association between hyperlactatemia and occult cardiac failure in diabetic patients on maintenance hemodialysis.

Varol U, Varol Y, Yaprak M, Uzum A, Cirit M.

Int Urol Nephrol. 2014 Aug;46(8):1639-44. doi: 10.1007/s11255-013-0630-9. Epub 2013 Dec 20.

PMID:
24356918
20.

Quantitative evaluation of interstitial fibrosis with Sirius Red in IgA nephritis.

Gibyeli Genek D, Sahin OZ, Çakalağaoğlu F, Özen Yeniay P, Yavas H, Ersoy R, Uzum A, Cirit M.

Ren Fail. 2014 Feb;36(1):73-7. doi: 10.3109/0886022X.2013.832311. Epub 2013 Sep 13.

PMID:
24028638
21.

The impact of membrane permeability and dialysate purity on cardiovascular outcomes.

Asci G, Tz H, Ozkahya M, Duman S, Demirci MS, Cirit M, Sipahi S, Dheir H, Bozkurt D, Kircelli F, Ok ES, Erten S, Ertilav M, Kose T, Basci A, Raimann JG, Levin NW, Ok E; EGE Study Group.

J Am Soc Nephrol. 2013 May;24(6):1014-23. doi: 10.1681/ASN.2012090908. Epub 2013 Apr 25.

22.

Prognostic value of NGAL staining in patients with IgA nephropathy.

Yavas H, Sahin OZ, Ersoy R, Taşlı F, Gibyeli Genek D, Uzum A, Cirit M.

Ren Fail. 2013;35(4):472-6. doi: 10.3109/0886022X.2013.767114. Epub 2013 Feb 18.

PMID:
23413884
23.

Evaluation of inhaler technique and patient satisfaction with fixed-combination budesonide/formoterol dry-powder inhaler in chronic obstructive pulmonary disease (COPD): data on real-life clinical practice in Turkey.

Öztürk C, Kaya A, Bilgin C, Yücesoy L, İkidağ B, Demirel M, Başlılar Ş, Şaylan B, Senol T, Ağanoğlu S, Can G, Doğrul MI, Çam M, Erdoğan N, Batum Ö, Turan MO, Demir C, Torun Ş, Cirit M, Turan M, Keleşoğlu A, Yaşar S, Uzunay Ö, Melek K, Altıparmak O.

Tuberk Toraks. 2012;60(4):301-13.

24.

Systemic perturbation of the ERK signaling pathway by the proteasome inhibitor, MG132.

Cirit M, Grant KG, Haugh JM.

PLoS One. 2012;7(11):e50975. doi: 10.1371/journal.pone.0050975. Epub 2012 Nov 30.

25.

Glomerular c4d staining can be an indicator of disease activity in lupus nephritis.

Sahin OZ, Gurses S, Taslı F, Yavas H, Ersoy R, Uzum A, Cirit M.

Ren Fail. 2013;35(2):222-5. doi: 10.3109/0886022X.2012.743916. Epub 2012 Nov 26.

PMID:
23176021
26.

The impact of low serum sodium level on mortality depends on glycemic control.

Sahin OZ, Asci G, Kircelli F, Yilmaz M, Duman S, Ozkahya M, Dogan C, Odabas AR, Cirit M, Ok E.

Eur J Clin Invest. 2012 May;42(5):534-40. doi: 10.1111/j.1365-2362.2011.02613.x. Epub 2011 Nov 3.

PMID:
22049913
27.

Quantitative models of signal transduction networks: How detailed should they be?

Cirit M, Haugh JM.

Commun Integr Biol. 2011 May;4(3):353-6. doi: 10.4161/cib.4.3.15149.

28.

The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction.

Avci E, Yeşil M, Bayata S, Postaci N, Arikan E, Cirit M.

Anadolu Kardiyol Derg. 2011 Nov;11(7):613-7. doi: 10.5152/akd.2011.164. Epub 2011 Sep 29.

30.

Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients.

Koc M, Dogan C, Arinsoy T, Tonbul Z, Ayli D, Cirit M, Sever MS, Yilmaz ME, Unsal A, Suleymanlar G, Ok E, Basci A, Yildiz A.

Hemodial Int. 2011 Jul;15(3):366-73. doi: 10.1111/j.1542-4758.2011.00547.x. Epub 2011 Apr 20.

PMID:
21507195
31.

Nutritional state alters the association between free triiodothyronine levels and mortality in hemodialysis patients.

Ozen KP, Asci G, Gungor O, Carrero JJ, Kircelli F, Tatar E, Sevinc Ok E, Ozkahya M, Toz H, Cirit M, Basci A, Ok E.

Am J Nephrol. 2011;33(4):305-12. doi: 10.1159/000324883. Epub 2011 Mar 8.

PMID:
21389695
32.

Allosteric modulation of Ras-GTP is linked to signal transduction through RAF kinase.

Buhrman G, Kumar VS, Cirit M, Haugh JM, Mattos C.

J Biol Chem. 2011 Feb 4;286(5):3323-31. doi: 10.1074/jbc.M110.193854. Epub 2010 Nov 22.

33.

Systematic quantification of negative feedback mechanisms in the extracellular signal-regulated kinase (ERK) signaling network.

Cirit M, Wang CC, Haugh JM.

J Biol Chem. 2010 Nov 19;285(47):36736-44. doi: 10.1074/jbc.M110.148759. Epub 2010 Sep 16.

34.

TLR polymorphisms in FMF: association of TLR-2 (Arg753Gln) and TLR-4 (Asp299Gly, Thre399Ile) polymorphisms and myeloid cell TLR-2 and TLR-4 expression with the development of secondary amyloidosis in FMF.

Soylu A, Ateş H, Cingöz S, Türkmen M, Demir BK, Tunca M, Sakızlı M, Cirit M, Ersoy R, Ulgenalp A, Kavukçu S.

Inflammation. 2011 Oct;34(5):379-87. doi: 10.1007/s10753-010-9245-9.

PMID:
20714796
35.

Stochastic model of integrin-mediated signaling and adhesion dynamics at the leading edges of migrating cells.

Cirit M, Krajcovic M, Choi CK, Welf ES, Horwitz AF, Haugh JM.

PLoS Comput Biol. 2010 Feb 26;6(2):e1000688. doi: 10.1371/journal.pcbi.1000688.

36.

The renal effect of replacement fluids in controlled severe hemorrhagic shock: an experimental study.

Adanir T, Aksun M, Cirit M, Alkan Taşli F, Sahin O, Kestelli M, Aydin Kantaroğlu T, Köseoğlu M, Sencan A, Karahan N.

Ulus Travma Acil Cerrahi Derg. 2009 Sep;15(5):423-32.

37.

PI3K-dependent cross-talk interactions converge with Ras as quantifiable inputs integrated by Erk.

Wang CC, Cirit M, Haugh JM.

Mol Syst Biol. 2009;5:246. doi: 10.1038/msb.2009.4. Epub 2009 Feb 17. Erratum in: Mol Syst Biol. 2011;7:524.

38.

Renal Behçet's disease: an update.

Akpolat T, Dilek M, Aksu K, Keser G, Toprak O, Cirit M, Oğuz Y, Taşkapan H, Adibelli Z, Akar H, Tokgöz B, Arici M, Celiker H, Diri B, Akpolat I.

Semin Arthritis Rheum. 2008 Dec;38(3):241-8. doi: 10.1016/j.semarthrit.2007.11.001. Epub 2008 Jan 25. Review.

PMID:
18221990
39.

An unusual vascular involvement in a patient with Behcet's disease: renal artery stenosis.

Toprak O, Ersoy R, Uzum A, Memis A, Cirit M, Akpolat T.

Am J Med Sci. 2007 Nov;334(5):396-8.

PMID:
18004096
40.

Preventive effect of nebivolol on contrast-induced nephropathy in rats.

Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahioglu M, Uzum A, Ersoy R, Sozmen EY.

Nephrol Dial Transplant. 2008 Mar;23(3):853-9. Epub 2007 Oct 12.

PMID:
17933840
41.

Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease.

Toprak O, Cirit M, Yesil M, Bayata S, Tanrisev M, Varol U, Ersoy R, Esi E.

Nephrol Dial Transplant. 2007 Mar;22(3):819-26. Epub 2006 Nov 7.

PMID:
17090607
42.

Risk factors and therapy strategies for contrast-induced nephropathy.

Toprak O, Cirit M.

Ren Fail. 2006;28(5):365-81. Review.

PMID:
16825085
43.

Risk factors for contrast-induced nephropathy.

Toprak O, Cirit M.

Kidney Blood Press Res. 2006;29(2):84-93. Epub 2006 May 16. Review.

44.

Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy.

Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, Esi E.

Nephron Clin Pract. 2006;104(1):c20-7. Epub 2006 May 9.

PMID:
16685140
45.

Metabolic syndrome as a risk factor for contrast-induced nephropathy in non-diabetic elderly patients with renal impairment.

Toprak O, Cirit M, Yesil M, Byrne DW, Postaci N, Bayata S, Majchrzak KM, Esi E.

Kidney Blood Press Res. 2006;29(1):2-9. Epub 2006 Mar 22.

46.

Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease.

Toprak O, Cirit M, Esi E, Postaci N, Yesil M, Bayata S.

Catheter Cardiovasc Interv. 2006 Feb;67(2):227-35.

PMID:
16400673
47.

Oral-facial-digital syndrome type 1, Caroli's disease and cystic renal disease.

Toprak O, Uzum A, Cirit M, Esi E, Inci A, Ersoy R, Tanrisev M, Ok E, Franco B.

Nephrol Dial Transplant. 2006 Jun;21(6):1705-9. Epub 2005 Dec 29. No abstract available.

PMID:
16384823
48.

New-onset type II diabetes mellitus, hyperosmolar non-ketotic coma, rhabdomyolysis and acute renal failure in a patient treated with sulpiride.

Toprak O, Cirit M, Ersoy R, Uzüm A, Ozümer O, Cobanoğlu A, Tanrisev M, Güleç D, Cetinkalp S.

Nephrol Dial Transplant. 2005 Mar;20(3):662-3. No abstract available.

PMID:
15735255
49.

Recurrent rhabdomyolysis and mild acute renal failure associated with acute Brucella infection.

Toprak O, Kaptan F, Cirit M, Ormen B, Uzum A, Ersoy R, Turker N.

Nephrol Dial Transplant. 2005 Apr;20(4):848-9. Epub 2005 Feb 16. No abstract available.

PMID:
15716295
50.

Investigating the volume status before contrast nephropathy studies.

Toprak O, Cirit M.

Nephrol Dial Transplant. 2005 Feb;20(2):464; author reply 464-6. No abstract available.

PMID:
15673702

Supplemental Content

Support Center